ArticleOncology letters2015
Effect of integrin receptor-targeted liposomal paclitaxel for hepatocellular carcinoma targeting and therapy.
Article in Oncology letters, 2015. The graph could read no effect estimate from its abstract, so it casts no vote on the map. It has been retracted, and should not be counted. Cited by 20 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
20 citing papers in PubMed, 43 citations in OpenAlex.
- Gelatin Coating for the Improvement of Stability and Cell Uptake of Hydrophobic Drug-Containing Liposomes.Molecules (Basel, Switzerland) · 2022Article
- Predicting therapeutic drugs for hepatocellular carcinoma based on tissue-specific pathways.PLoS computational biology · 2021Article
- ApoE-modified liposomes mediate the antitumour effect of survivin promoter-driven HSVtk in hepatocellular carcinoma.Cancer gene therapy · 2020Article
- Preparation, Characterization, and Pharmacokinetic Study of a Novel Long-Acting Targeted Paclitaxel Liposome with Antitumor Activity.International journal of nanomedicine · 2020Article
- Nanocarrier-mediated antioxidant delivery for liver diseases.Theranostics · 2020Review
- Cancer nanotechnology: Enhancing tumor cell response to chemotherapy for hepatocellular carcinoma therapy.Asian journal of pharmaceutical sciences · 2019Review
- The emerging role of microRNAs and long noncoding RNAs in drug resistance of hepatocellular carcinoma.Molecular cancer · 2019Review
- Polymer-Mediated Delivery of siRNAs to Hepatocellular Carcinoma: Variables Affecting Specificity and Effectiveness.Molecules (Basel, Switzerland) · 2018Review
- Docetaxel-trastuzumab stealth immunoliposome: development and in vitro proof of concept studies in breast cancer.International journal of nanomedicine · 2018Article
- Magnetic Resonance Gd-RGD Imaging Study of Hepatocellular Carcinoma with High and Low Metastatic Potential before and after Human Bone Marrow-derived Mesenchymal Stem Cell Intervention.Chinese medical journal · 2017Article
- Asialoglycoprotein receptor targeted delivery of doxorubicin nanoparticles for hepatocellular carcinoma.Drug delivery · 2017Article
- Evaluation of pharmacokinetic and pharmacodynamic profiles of liposomes for the cell type-specific delivery of small molecule drugs.Nanomedicine : nanotechnology, biology, and medicine · 2017Article
- Glycyrrhetinic Acid Liposomes Containing Mannose-Diester Lauric Diacid-Cholesterol Conjugate Synthesized by Lipase-Catalytic Acylation for Liver-Specific Delivery.Molecules (Basel, Switzerland) · 2017Article
- RGD-Modified Albumin Nanoconjugates for Targeted Delivery of a Porphyrin Photosensitizer.Molecular pharmaceutics · 2017Article
- Recent advances in hepatocellular carcinoma therapy.Pharmacology & therapeutics · 2017Review
- ATF2 translation is induced under chemotherapeutic drug-mediated cellular stress via an IRES-dependent mechanism in human hepatic cancer Bel7402 cells.Oncology letters · 2016Article
- Alpha fetoprotein antagonizes apoptosis induced by paclitaxel in hepatoma cells in vitro.Scientific reports · 2016Article
- Recent insights in nanotechnology-based drugs and formulations designed for effective anti-cancer therapy.Journal of nanobiotechnology · 2016Review
- Effect of Combined Treatment Using Wilfortrine and Paclitaxel in Liver Cancer and Related Mechanism.Medical science monitor : international medical journal of experimental and clinical research · 2016Article
- Ligand-based targeted therapy: a novel strategy for hepatocellular carcinoma.International journal of nanomedicineReview
Corrections and comments
- Retraction · 2021-03-04Concerns/Issues about Authorship/Affiliation · Concerns/Issues about Data · Concerns/Issues about Image · Concerns/Issues about Results and/or Conclusions · Duplication of/in Image · Objections by Third Party · Paper Mill · · see also: https://pubpeer.com/publications/93466560B8B4C5E737A9F93F8E06D8;
- Retracted
Authors and funding
4 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The major aim of the present study was to develop an integrin receptor-targeted liposomal paclitaxel (PTX) to enhance the targeting specificity and therapeutic effect of PTX on hepatocellular carcinoma (HCC) cells. The specific Arg-Gly-Asp (RGD) ligand was conjugated to 1,2-distearoylphosphatidylethanolamine-polyethylene glycol 2000 to prepare the RGD-modified liposomes (RGD-LP). Furthermore, physicochemical characteristics of RGD-LP, including particle size, ζ potential, encapsulation efficiency and
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.